ROXICLOT 10MG TABLET
RIVAROXIBAN
What it does
Rivaroxaban is a medication that helps prevent blood clots, reducing the risk of serious conditions such as stroke and heart attack.
Commonly used for: prevention of blood clots in patients with atrial fibrillation (irregular heartbeat), treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), prevention of blood clots after certain surgeries
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:56:22 · updated 2026-08-03 03:05:40
About this medicine
Rivaroxaban is a medication that helps prevent blood clots, reducing the risk of serious conditions such as stroke and heart attack.
What it treats
- prevention of blood clots in patients with atrial fibrillation (irregular heartbeat)
- treatment of deep vein thrombosis (DVT)
- treatment of pulmonary embolism (PE)
- prevention of blood clots after certain surgeries
How it works
Rivaroxaban works by blocking specific proteins in your blood that are necessary for clotting, which helps keep your blood flowing smoothly.
Who it's for
This medication is for adults who need help preventing or treating blood clots.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: rivaroxiban
Rivaroxaban is an oral anticoagulant that belongs to the class of direct factor Xa inhibitors. It is primarily used for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban works by inhibiting factor Xa, an essential component in the coagulation cascade, thereby reducing the ability of blood to clot.
Indications
- Prevention of venous thromboembolism (VTE) in patients undergoing hip or knee replacement surgery
- Treatment of DVT and PE
- Prevention of recurrent DVT and PE
- Stroke prevention in patients with non-valvular atrial fibrillation
- Prevention of thromboembolic events in patients with coronary artery disease
Dosage
Children: Refer to the BNF for Children for specific dosing recommendations for paediatric patients.
Adults: Refer to the BNF for specific dosing recommendations based on the indication and patient factors.
Mechanism of action
Rivaroxaban selectively inhibits factor Xa, which is crucial in the conversion of prothrombin to thrombin, leading to a reduction in thrombin generation and a consequent decrease in fibrin formation.
Pharmacodynamics
Rivaroxaban has a rapid onset of action and provides predictable anticoagulation with a dose-dependent effect. Its anticoagulant effect can be monitored through standard coagulation tests like prothrombin time, although routine monitoring is not required in most cases. The anticoagulation effects are maintained as long as the drug is present in the system.
Pharmacokinetics
Rivaroxaban is well absorbed after oral administration, with peak plasma concentrations occurring within 2 to 4 hours. It has a bioavailability of approximately 66% to 100%. The drug is extensively metabolized in the liver, with a half-life of about 5 to 9 hours in healthy individuals. Rivaroxaban is primarily excreted in urine, with a proportion being eliminated unchanged.
Contra-indications
- Active bleeding
- Severe renal impairment (creatinine clearance < 15 mL/min)
- Hepatic impairment with coagulopathy
- Pregnancy
- Hypersensitivity to rivaroxaban or any excipients
Adverse effects
- Bleeding complications
- Anemia
- Nausea
- Vomiting
- Diarrhea
- Elevated liver enzymes
- Skin rash
- Thrombocytopenia
Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) increase rivaroxaban exposure
- Strong CYP3A4 inducers (e.g., rifampicin, St. John's wort) decrease rivaroxaban exposure
- Anticoagulants (e.g., warfarin, dabigatran) may increase bleeding risk
- NSAIDs may increase the risk of gastrointestinal bleeding
- Antiplatelet agents may enhance the risk of bleeding
Precautions
- Use with caution in patients with a history of bleeding disorders
- Monitor renal function regularly
- Avoid abrupt discontinuation in patients at high risk for thromboembolic events
- Patients should be monitored for signs of bleeding
Pregnancy
Rivaroxaban is contraindicated in pregnancy due to potential risks to the fetus.
Breast-feeding
It is not known if rivaroxaban is excreted in human milk. Caution is advised when administering to nursing mothers.
Storage
Store at room temperature, away from moisture and heat. Keep out of reach of children.
Formulations
- Tablets (10 mg, 15 mg, 20 mg)
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.